NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $48.60 Consensus Price Target from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $48.60.

A number of equities research analysts recently issued reports on NAMS shares. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC raised their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Truist Financial started coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target for the company. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Finally, Guggenheim raised their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. This trade represents a 72.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC raised its position in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN raised its position in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV bought a new stake in NewAmsterdam Pharma during the 1st quarter valued at $37,000. Navalign LLC purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $46,000. Finally, AdvisorNet Financial Inc purchased a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $82,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $29.33 on Thursday. The firm has a market capitalization of $3.43 billion, a price-to-earnings ratio of -16.39 and a beta of 0.07. NewAmsterdam Pharma has a 1 year low of $17.63 and a 1 year high of $42.21. The business has a 50 day simple moving average of $33.53 and a 200-day simple moving average of $33.77.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. As a group, analysts expect that NewAmsterdam Pharma will post -1.78 earnings per share for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.